Goal 3: Advance Translational Research

Maximizing anti-tumor immunity following allogeneic HCT with biomarkers

Allogeneic hematopoietic cell transplantation (allo-HCT) is one of the most effective forms of tumor immunotherapy available to date. Allo-HCT can be life-saving for patients with aggressive malignancies that cannot be cured through other strategies. The immunotherapeutic efficacy of allo-HCT depends on donor T cell recognition of alloantigens on leukemic cells, which is known as the graft-versus-tumor effect (GVT). No blood tests are currently available to predict whether GVT will occur. The critical challenge is aimed at developing biologically relevant, accurate and simple laboratory tests to predict GVT without graft-versus-host disease (GVHD). The ultimate goal is to identify and validate biomarkers that separate GVT and GVHD.

Tags (Keywords associated with the idea)


32 net votes
52 up votes
20 down votes
Idea No. 604